TransAlgae

Algae-based Drug-delivery Platform

Health Tech & Life Sciences
Active
Mature Rehovot, Israel Founded 2008
LinkedIn
Last updated 2026-06-18
Total raised
$29.5M
Last: Undisclosed Round 2021-04
Stage
Mature
Founded
2008
Headcount
12
HQ
Rehovot, Israel
Sector
Health Tech & Life Sciences

About

TransAlgae develops an algae-based platform for the oral delivery of drugs (vaccines, immune modulators, insecticides, etc.) for human and animal health and for crop protection. TransAlgae's drug-delivery platform was demonstrated on mice as a model for humans. TransAlgae successfully demonstrated that proteins, expressed in algae, were orally delivered to the mice blood and liver in their intact form, due to the native bio-encapsulation of the algae and the formulation that TransAlgae has developed. In the area of animal health, TransAlgae's oral-delivery technology replaces the need for antibiotics and vaccination by injections. The company's algal powder, containing the desired drug or vaccine, is used as a feed supplement, enabling vaccination by feeding. TransAlgae has also developed a proprietary platform for the delivery of biological-based insecticides to be sprayed on crops. The technology enables targeting particular insects in a specific manner, replacing the need for toxic chemicals. The genetically modified algae are inactive, thus not affecting humans, animals, or crops, and are classified as a GMO-derived material.

Funding history · 6 rounds · $29.5M total

Date unknown
Undisclosed Round $3.0M
Date unknown
GrantEvent $1.5M
2008-05
A Round $12.0M
2016-03
Convertible Debt $10.0M
2017-11
GrantEvent $520K
2021-04
Undisclosed Round $2.5M

Q&A

What is TransAlgae's primary focus?
TransAlgae develops an algae-based platform for the oral delivery of drugs such as vaccines, immune modulators, and insecticides for human and animal health, and for crop protection.
When was TransAlgae founded?
TransAlgae was founded in May 2008.
What is TransAlgae's employee count?
TransAlgae has 11-50 employees.
What is the total amount of funding TransAlgae has raised to date?
TransAlgae has raised a total of $29,519,750 USD.
Who are the co-founders of TransAlgae?
The co-founders of TransAlgae are Maor Sasson (CEO), Doron Eisenstadt (COO), and Ofra Chen (CTO).
What is TransAlgae's approach to animal health?
TransAlgae's oral-delivery technology for animal health uses an algal powder as a feed supplement to enable vaccination by feeding, aiming to replace antibiotics and vaccination by injections.
How does TransAlgae address crop protection?
TransAlgae has developed a proprietary platform for delivering biological-based insecticides that can be sprayed on crops, targeting specific insects and reducing the need for toxic chemicals.

Team · 3

Founder · Co-founder & CEO
LinkedIn ↗
Founder · Co-founder
LinkedIn ↗
Founder · Co-founder & CTO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Climate TechFood & Land UseSustainable FarmingHealth Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Technologies
BiologicalsCells
Target customers
Agriculture & FoodCropsMarine LifeSea FoodFishLivestockHealthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2CB2B

Highlights

1 PatentsVerified

Tags

veterinaryalgaebiotechnologyagtechlivestockclimate-techpest-controldrug-deliveryplant-protectionanimal-healthpharmaceuticalsvaccinessustainable-farming
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

LinkedInlinkedin.com/company/627820

Identifiers & details

Founded2008-5
Employees (exact)12

Radar intelligence

Patents

EPO16

Web history (Wayback)

Domaintransalgae.com